Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Birth outcomes of pregnancies fathered by men with multiple sclerosis.
Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis.
An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients.
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
A controlled trial of natalizumab for relapsing multiple sclerosis.
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis.
Four Square Step Test in ambulant persons with multiple sclerosis: validity, reliability, and responsiveness.
Structure and Activity of the Acid Sensing Ion Channels.
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Absence of mannose-binding lectin in a female with relapsing-remitting multiple sclerosis.
Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.
Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis.
Disease-modifying therapies in Chinese children with multiple sclerosis.
RORγt(+) cells selectively express redundant cation channels linked to the Golgi apparatus.
Fatigue in multiple sclerosis - A brief review.
Oligodendrocytes Enforce Immune Tolerance of the Uninfected Brain by Purging the Peripheral Repertoire of Autoreactive CD8(+) T Cells.
Disease-modifying drugs for multiple sclerosis and JC virus expression.
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Genzyme to Resubmit LemtradaTM Application for FDA Review
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Teva to initiate third Phase III trial of oral laquinimod for the treatment of relapsing remitting multiple sclerosis
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.

Pages